

**Table 1. Current Clinical Trials**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>ADOPTIVE IMMUNOTHERAPY</b>				
Reconstitution of HIV-specific immunity against HIV	<a href="#">NCT02563509</a>	Guangzhou 8th People's Hospital	Phase I/II	December 2017
HXTC: HIV 1 antigen expanded specific T cell therapy	<a href="#">NCT02208167</a>	University of North Carolina, Chapel Hill	Phase I	September 2018
<b>ANTIBODIES</b>				
<b>vedolizumab</b> (anti- $\alpha_4\beta_7$ integrin antibody)	<a href="#">NCT03147859</a> (not yet open for enrollment)	Ottawa Hospital Research Institute	Phase II	December 2018
<b>VRC01</b> (broadly neutralizing monoclonal antibody)	<a href="#">NCT02664415</a> (closed to enrollment)	National Institute of Allergy and Infectious Diseases (NIAID)	Phase II	July 2017
<b>3BNC117</b> (broadly neutralizing monoclonal antibody)	<a href="#">NCT02446847</a> (closed to enrollment)	Rockefeller University	Phase I/II	March 2018
<b>3BNC117</b>	<a href="#">NCT02588586</a> (closed to enrollment)	Rockefeller University	Phase I/II	March 2018
<b>10-1074</b> (broadly neutralizing monoclonal antibody)	<a href="#">NCT02511990</a> (closed to enrollment)	Rockefeller University	Phase I	July 2017
<b>3BNC117 + 10-1074</b>	<a href="#">NCT02825797</a>	Rockefeller University	Phase I	June 2018
<b>PGT121</b>	<a href="#">NCT02960581</a> (enrolling by invitation only)	International AIDS Vaccine Initiative	Phase I	March 2018
<b>vedolizumab</b> (anti- $\alpha_4\beta_7$ integrin antibody)	<a href="#">NCT02788175</a>	NIAID	Phase I	May 2020
<b>VRC01LS</b> (long-acting broadly neutralizing monoclonal antibody)	<a href="#">NCT02840474</a>	NIAID	Phase I	August 2018
<b>VRC01</b> in acute HIV infection	<a href="#">NCT02591420</a>	NIAID	Phase I	April 2018
<b>VRC01</b>	<a href="#">NCT02471326</a> (closed to enrollment)	NIAID	Phase I	June 2018
<b>ANTI-FIBROTIC</b>				
<b>losartan</b>	<a href="#">NCT01852942</a>	University of Minnesota	Phase II	July 2018
<b>telmisartan</b>	<a href="#">NCT02170246</a>	Yale University	Phase I	February 2019

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>ANTI-INFLAMMATORY</b>				
canakinumab (IL-1 $\beta$ inhibitor)	<a href="#">NCT02272946</a>	University of California, San Francisco	Phase II	June 2018
metformin	<a href="#">NCT02659306</a>	McGill University Health Center	Phase I	October 2017
<b>ANTIRETROVIRAL THERAPY</b>				
dolutegravir in reservoirs	<a href="#">NCT02924389</a>	Emory University	Phase N/A	June 2020
ABX464	<a href="#">NCT02990325</a>	Abivax S.A.	Phase I/II	March 2018
<b>COMBINATIONS</b>				
maraviroc, dolutegravir, dendritic cell vaccine, auranofin, nicotinamide	<a href="#">NCT02961829</a> (closed to enrollment)	Federal University of São Paulo	Not listed	July 2017
Perturbing of HIV reservoir with immune stimulation: Fluarix, Pneumovax vaccines	<a href="#">NCT02707692</a>	University of California, San Diego	Not listed	January 2021
Impact of <b>Sirolimus</b> and <b>maraviroc</b> on CCR5 expression and the HIV-1 reservoir in HIV+ kidney transplant recipients	<a href="#">NCT02990312</a>	University of Maryland	Phase IV	July 2020
<b>ROADMAP</b> : romidepsin + 3BNC117	<a href="#">NCT02850016</a>	Rockefeller University	Phase IIa	December 2018
<b>eCLEAR</b> : romidepsin + 3BNC117	<a href="#">NCT03041012</a>	Aarhus University Hospital	Phase II	August 2019
<b>panobinostat + pegylated interferon-alpha2a</b>	<a href="#">NCT02471430</a>	Massachusetts General Hospital	Phase II	February 2020
<b>Research In Viral Eradication of HIV Reservoirs (RIVER)</b> : ART, ChAdV63.HIVconsV & MVA.HIVconsV vaccines, vorinostat	<a href="#">NCT02336074</a> <a href="#">UK CPMS18010</a> (closed to enrollment)	Imperial College London	Phase II	July 2018
<b>disulfiram + vorinostat</b>	<a href="#">NCT03198559</a>	The Peter Doherty Institute for Infection and Immunity	Phase I/II	July 2027
<b>SB-728mR-T</b> (autologous CD4 T cells genetically modified at the CCR5 gene) + <b>cyclophosphamide</b>	<a href="#">NCT02225665</a> (closed to enrollment)	Sangamo BioSciences	Phase I/II	June 2018
<b>SB-728-T + cyclophosphamide</b>	<a href="#">NCT01543152</a> (closed to enrollment)	Sangamo BioSciences	Phase I/II	September 2016
<b>AGS-004 + vorinostat</b>	<a href="#">NCT02707900</a>	NIAID	Phase I	December 2019

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>COMBINATIONS (Cont.)</b>				
<b>CD4-ZETA</b> gene-modified T cells +/- interleukin-2 (IL-2)	<a href="#">NCT01013415</a> (closed to enrollment)	University of Pennsylvania	Phase I	July 2021
<b>DCV3</b> (dendritic cell-based vaccine pulsed with autologous inactivated HIV) + pegylated interferon	<a href="#">NCT02767193</a>	Judit Pich Martínez, Fundació Clínic per la Recerca Biomèdica	Phase I	June 2018
<b>MVA.HIVconsV + romidepsin</b>	<a href="#">NCT02616874</a> (closed to enrollment)	IrsiCaixa	Phase I	October 2017
<b>SB-728mR-T + cyclophosphamide</b>	<a href="#">NCT02388594</a>	University of Pennsylvania	Phase I	December 2018
<b>vorinostat + HXTC: HIV 1 antigen expanded specific T cell therapy</b>	<a href="#">NCT03212989</a>	Julia Sung, MD, University of North Carolina, Chapel Hill	Phase I	June 2021
<b>GENE THERAPIES</b>				
<b>Cal-1: Dual anti-HIV gene transfer construct</b>	<a href="#">ACTRN12615000763549</a>	Calimmune	Phase I/II	N/A
<b>Cal-1: Dual anti-HIV gene transfer construct</b>	<a href="#">NCT01734850</a> (closed to enrollment) <a href="#">NCT02390297</a> (long term safety phase)	Calimmune	Phase I/II	October 2017 January 2032
<b>VRX496</b> (gene-modified autologous CD4 T cells)	<a href="#">NCT00295477</a> (closed to enrollment)	University of Pennsylvania	Phase I/II	December 2020
<b>SB-728mR-HSPC</b> (autologous hematopoietic stem/progenitor cells genetically modified at the CCR5 gene)	<a href="#">NCT02500849</a>	City of Hope Medical Center	Phase I	July 2018
<b>MazF-T</b> (redirected MazF-CD4 autologous T cells)	<a href="#">NCT01787994</a> (closed to enrollment)	Takara Bio/University of Pennsylvania	Phase I	December 2016
<b>C34-CXCR4</b> (autologous CD4 T cells gene-modified to express HIV-inhibiting peptide C34)	<a href="#">NCT03020524</a>	University of Pennsylvania	Phase 0	January 2018
<b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>				
Stem cells gene-modified with CCR5 shRNA/TRIM5alpha/TAR decoy	<a href="#">NCT02797470</a>	AIDS Malignancy Consortium	Phase I/II	September 2019
Stem cells gene-modified with C46/CCR5/P140K	<a href="#">NCT02343666</a>	Fred Hutchinson Cancer Research Center	Phase I	August 2020

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS (Cont.)</b>				
Stem cells gene-modified with <b>Cal-1</b>	<a href="#">NCT02378922</a> (suspended)	Fred Hutchinson Cancer Research Center	Phase I	June 2019
CRISPR CCR5 modified CD34+ cells	<a href="#">NCT03164135</a>	307 Hospital of PLA (Affiliated Hospital of Academy to Military Medical Sciences)	Not listed	May 20, 2021
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	<a href="#">NCT02337985</a>	City of Hope Medical Center	Not listed	June 2031
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ) + busulfan	<a href="#">NCT01961063</a>	City of Hope Medical Center	Not listed	October 2030
Stem cells gene-modified to encode multiple anti-HIV RNAs (rHIV7-shI-TAR-CCR5RZ)	<a href="#">NCT00569985</a> (closed to enrollment)	City of Hope Medical Center	Not listed	December 2015
<b>HORMONES</b>				
<b>somatotropin</b> (human growth hormone)	<a href="#">NCT03091374</a>	McGill University Health Center	Phase II	June 2019
<b>IMAGING STUDIES</b>				
Radiolabeled broadly neutralizing anti-HIV antibody 3BNC117 + Copper-64 radio isotope followed by MRI/PET scanning to detect HIV in vivo	<a href="#">NCT03063788</a> (not yet open for enrollment)	Bayside Health	Phase I	December 2017
<b>IMMUNE CHECKPOINT INHIBITORS</b>				
<b>durvalumab</b> (anti-PD-L1 antibody) in solid tumors	<a href="#">NCT03094286</a>	Spanish Lung Cancer Group	Phase II	April 2022
<b>nivolumab</b> (anti-PD-1 antibody) + <b>ipilimumab</b> (anti-CTLA-4 antibody) in treating patients with advanced HIV associated solid tumors	<a href="#">NCT02408861</a>	National Cancer Institute (NCI)	Phase I	December 2020
<b>pembrolizumab</b> (anti-PD-1 antibody) in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms	<a href="#">NCT02595866</a>	National Cancer Institute (NCI)	Phase I	April 2018
<b>JANUS KINASE INHIBITORS</b>				
<b>ruxolitinib</b>	<a href="#">NCT02475655</a>	NIAID	Phase II	October 2016

Table 1. Current Clinical Trials (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>LATENCY-REVERSING AGENTS</b>				
<b>Chidamide</b>	<a href="#">NCT02902185</a>	Tang-Du Hospital	Phase II/III	December 2018
<b>Poly-ICLC</b> (TLR-3 agonist)	<a href="#">NCT02071095</a> (closed to enrollment)	Nina Bhardwaj, MD/Campbell Foundation/Oncovir, Inc.	Phase I/II	June 2017
<b>romidepsin</b> (HDAC inhibitor)	<a href="#">NCT01933594</a>	AIDS Clinical Trials Group/NIAID/Gilead	Phase I/II	August 2017
<b>vesatolimod</b> (TLR-7 agonist) in ART-treated HIV controllers	<a href="#">NCT03060447</a>	Gilead Sciences	Phase Ib	September 2018
<b>vesatolimod</b> (formerly GS-9620) (TLR-7 agonist)	<a href="#">NCT02858401</a> (closed to enrollment)	Gilead Sciences	Phase Ib	December 2016
<b>ALT-803</b> (recombinant human super agonist interleukin-15 complex)	<a href="#">NCT02191098</a>	University of Minnesota - Clinical and Translational Science Institute	Phase I	June 2016
<b>Kansui</b> (traditional Chinese medicine containing ingenols)	<a href="#">NCT02531295</a> (suspended)	UCSF	Phase I	December 2019
<b>mTOR INHIBITORS</b>				
Impact of <b>Everolimus</b> on HIV persistence post kidney or liver transplant	<a href="#">NCT02429869</a>	UCSF	Phase IV	June 2017
<b>Sirolimus</b>	<a href="#">NCT02440789</a>	ACTG	Phase I/II	December 2016
<b>PROTEASOME INHIBITORS</b>				
<b>ixazomib</b>	<a href="#">NCT02946047</a>	Nathan W. Cummins, M.D.	Phase I/II	September 2019
<b>STEM CELL TRANSPLANTATION</b>				
<b>HIVECT</b> : HIV eradication through cord-blood transplantation	<a href="#">NCT02923076</a>	Puerta de Hierro University Hospital	N/A	December 2018
<b>IMPAACT P1107</b> : Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease	<a href="#">NCT02140944</a>	IMPAACT/NIAID/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	March 2023
<b>BMT CTN 0903</b> : Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection	<a href="#">NCT01410344</a> (closed to enrollment)	National Heart, Lung, & Blood Institute/National Cancer Institute/Blood & Marrow Transplant Clinical Trials Network	Phase II	November 2015

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>STEM CELL TRANSPLANTATION (Cont.)</b>				
Maraviroc in HIV-1+ individuals requiring allogeneic hematopoietic cell transplant	<a href="#">NCT03118661</a> (not yet open for enrollment)	Washington University School of Medicine	Phase I	May 2025
<b>THERAPEUTIC VACCINES</b>				
<b>iHIVARNA-01</b> (TriMix & HIV antigen naked messenger RNA)	<a href="#">NCT02888756</a>	Rob Gruters, Erasmus Medical Center	Phase IIa	November 2017
<b>GTU-multiHIV + LIPO-5</b> (DNA + lipopeptide vaccines)	<a href="#">NCT01492985</a> (closed to enrollment)	French National Institute for Health and Medical Research/French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	Phase II	October 2017
<b>GTU-MultiHIV B-clade + MVA HIV-B</b> (DNA + viral vector vaccines)	<a href="#">NCT02972450</a> (not yet open for enrollment)	Inserm/ANRS	Phase II	July 2018
<b>VAC-3S</b> (peptide-based vaccine)	<a href="#">NCT02041247</a> (closed to enrollment)	InnaVirVax	Phase II	November 2016
<b>VAC-3S</b>	<a href="#">NCT02390466</a> (closed to enrollment)	InnaVirVax	Phase I/IIa	April 2017
<b>Tat Oyi</b> (protein-based vaccine)	<a href="#">NCT01793818</a> (closed to enrollment)	Biosantech	Phase I/II	March 2016
<b>THV01</b> (lentiviral vector-based therapeutic vaccine)	<a href="#">NCT02054286</a> (closed to enrollment)	Theravectys S.A.	Phase I/II	March 2019
<b>Ad26.Mos.HIV + MVA-Mosaic</b>	<a href="#">NCT02919306</a> (closed to enrollment)	Janssen Vaccines & Prevention B.V.	Phase I	May 2019
Recombinant adenovirus type 5 vaccine	<a href="#">NCT02762045</a>	Centers for Disease Control and Prevention, China	Phase I	December 2017
<b>iHIVARNA-01</b> (TriMix & HIV antigen naked messenger RNA)	<a href="#">NCT02413645</a> (closed to enrollment)	Biomedical Research Institute August Pi i Sunyer (IDIBAPS)	Phase I	October 2016
<b>MAG-pDNA + rVSV<sub>IN</sub> HIV-1 Gag</b> (DNA + viral vector vaccines)	<a href="#">NCT01859325</a> (closed to enrollment)	NIAID/Profectus Biosciences, Inc.	Phase I	November 2016

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>TRADITIONAL CHINESE MEDICINE</b>				
<b>Triptolide wilfordii</b>	<a href="#">NCT02219672</a>	Peking Union Medical College	Phase III	July 2017
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>				
<b>LEOPARD:</b> Latency and early neonatal provision of antiretroviral drugs clinical trial	<a href="#">NCT02431975</a>	Columbia University	Not listed	July 2020
<b>New Era Study:</b> Treatment with multi-drug class (MDC) HAART	<a href="#">NCT00908544</a> (closed to enrollment)	MUC Research GmbH	Not listed	November 2019
Antiretroviral regime for viral eradication in newborns	<a href="#">NCT02712801</a>	National Center for Women and Children's Health, China CDC	Phase IV	December 2018
<b>DGVTRU:</b> Immediate initiation of antiretroviral therapy during "hyperacute" HIV infection	<a href="#">NCT02656511</a>	UCSF	Phase IV	January 2018
<b>DIORR:</b> Dolutegravir impact on residual replication	<a href="#">NCT02500446</a> (closed to enrollment)	University of Melbourne	Phase IV	December 2016
<b>DRONE:</b> Impact of starting a dolutegravir-based regimen on HIV-1 proviral DNA reservoir of treatment naïve and experienced patients	<a href="#">NCT02370979</a>	University Hospital, Strasbourg, France	Phase IV	July 2017
<b>AAHIV:</b> Antiretroviral therapy for acute HIV infection	<a href="#">NCT00796263</a>	South East Asia Research Collaboration with Hawaii	Phase III	July 2019
<b>tenofovir/emtricitabine + dolutegravir or tenofovir/emtricitabine + darunavir/cobicistat</b>	<a href="#">NCT02987530</a> (not yet open for enrollment)	French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	Phase III	December 2019
<b>VIRECURE:</b> Impact of extremely early ART to reduce viral reservoir & induce functional cure of HIV infection	<a href="#">NCT02588820</a>	David Garcia Cinca, Hospital Clinic of Barcelona	Phase III	May 2017
<b>EIT:</b> Early infant HIV treatment in Botswana	<a href="#">NCT02369406</a>	Harvard School of Public Health	Phase II/III	February 2019
<b>EARLIER:</b> Early ART to limit infection and establishment of reservoir	<a href="#">NCT02859558</a>	AIDS Clinical Trials Group	Phase II	December 2019
<b>peginterferon alfa-2b</b>	<a href="#">NCT02227277</a>	The Wistar Institute	Phase II	January 2018
<b>peginterferon alfa-2b</b>	<a href="#">NCT01935089</a> (closed to enrollment)	University of Pennsylvania/Wistar Institute	Phase II	July 2016

**Table 1. Current Clinical Trials (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>				
<b>IMPAACT P1115:</b> Very early intensive treatment of HIV-infected infants to achieve HIV remission	<a href="#">NCT02140255</a>	IMPAACT/NIAID/NICHD	Phase I/II	April 2022

**Table 2. Observational Studies**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
<b>ACTG A5321:</b> Decay of HIV-1 reservoirs in subjects on long-term antiretroviral therapy: The ACTG HIV reservoirs cohort (AHRC) study	Not listed yet, see <a href="#">ACTG website entry</a> for information	AIDS Clinical Trials Group	N/A	N/A
Analytic treatment interruption (ATI) to assess HIV cure	<a href="#">NCT02437526</a> (enrolling by invitation only)	Mayo Clinic	N/A	May 2020
<b>APACHE:</b> Monitored antiretroviral pause in chronically infected HIV+ individuals with long-lasting suppressed viremia	<a href="#">NCT03198325</a>	Ospedale San Raffaele	N/A	April 2018
Biomarkers to predict time to plasma HIV RNA rebound	<a href="#">NCT03001128</a>	AIDS Clinical Trials Group	N/A	December 2020
<b>CLEAC:</b> Comparison of late versus early antiretroviral therapy in HIV-infected children	<a href="#">NCT02674867</a>	French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	N/A	December 2018
<b>CODEX</b> (the “Extreme” cohort)	<a href="#">NCT01520844</a>	Inserm/ANRS	N/A	February 2018
<b>Developing a functional cure for HIV disease: Clinical specimen collection from HIV+ individuals</b>	<a href="#">NCT03215004</a>	<b>American Gene Technologies International Inc.</b>	N/A	July 2018
Effects of dolutegravir based regimen on HIV-1 reservoir and immune activation	<a href="#">NCT02557997</a>	University Hospital, Strasbourg, France	N/A	September 2016
<b>EPIC4:</b> Early Pediatric Initiation: Canada Child cure Cohort Study	<a href="#">CTN S 281</a>	Canadian Institutes of Health Research (CIHR)/Canadian Foundation for AIDS Research (CANFAR)/International AIDS Society (IAS)	N/A	December 2018



**Table 2. Observational Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
Establish and characterize an acute HIV infection cohort in a high-risk population	<a href="#">NCT00796146</a>	Southeast Asia Research Collaboration with Hawaii/Armed Forces Research Institute of Medical Sciences/Thai Red Cross AIDS Research Centre	N/A	July 2019
<b>EURECA:</b> Exploratory study of cellular reservoirs in blood	<a href="#">NCT02858414</a>	Centre Hospitalier Universitaire de Besancon	N/A	December 2017
Genotyping FcγRs genes	<a href="#">NCT03130296</a>	University Hospital, Strasbourg, France	N/A	April 2020
<b>HEATHER:</b> HIV reservoir targeting with early antiretroviral therapy	UK CPMS17589 (link currently broken)	University of Oxford/Medical Research Council/British HIV Association	N/A	September 2019
<b>HIV-STAR:</b> HIV sequencing after treatment interruption to identify the clinically relevant anatomical reservoir	<a href="#">NCT02641756</a> (closed to enrollment)	University Hospital, Ghent	N/A	December 2019
Host & viral factors associated with HIV elite control	UK CPMS16146 (link currently broken)	University College London Hospitals NHS Foundation Trust	N/A	May 2021
<b>HSCT-HIV:</b> Allogeneic hematopoietic stem cell transplantation in HIV-1 infected patients	<a href="#">NCT02732457</a>	Kirby Institute	N/A	September 2019
Identification and quantification of HIV CNS latency biomarkers	<a href="#">NCT02989285</a>	St Vincent's Hospital, Sydney	N/A	December 2020
<b>ImmunoCo27:</b> Co-adaptation between HIV and CD8 cellular immunity	<a href="#">NCT02886416</a>	French National Agency for Research on AIDS and Viral Hepatitis (Inserm/ANRS)	N/A	September 2018
Impact of ART adherence on HIV persistence and inflammation	<a href="#">NCT02797093</a>	University of Colorado, Denver	N/A	September 2017
<b>ISALA:</b> Analytical treatment interruption in HIV positive patients	<a href="#">NCT02590354</a>	Institute of Tropical Medicine, Belgium	N/A	November 2017
<b>LoViReT:</b> Low viral reservoir treated patients	<a href="#">NCT02972931</a> (not yet open for enrollment)	IrsiCaixa	N/A	December 2017
Post analytic treatment interruption study	<a href="#">NCT02761200</a>	South East Asia Research Collaboration with Hawaii	N/A	June 2020

**Table 2. Observational Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Estimated Study Completion Date
Predictors of time to viremia with an analytic treatment interruption	<a href="#">NCT03033017</a>	University of Minnesota - Clinical and Translational Science Institute	N/A	July 2018
Quantitative measurement and correlates of the latent HIV reservoir in virally suppressed Ugandans	<a href="#">NCT02154035</a>	NIAID	N/A	December 2019
<b>TESOVIR:</b> Tracking and exploring the source of viral rebound (ART interruption)	<a href="#">NCT03117985</a>	Centre Hospitalier Régional d'Orléans	N/A	February 2018
The use of leukapheresis to support HIV pathogenesis studies	<a href="#">NCT01161199</a>	University of California, San Francisco	N/A	July 2020

**Table 3. Completed Studies**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ADOPTIVE IMMUNOTHERAPY</b>				
Early ART in combination with autologous HIV-specific cytotoxic T lymphocyte (CTL) infusion	<a href="#">NCT02231281</a>	Yongtao Sun, MD, PhD, Tangdu Hospital, the Fourth Military Medical University	Phase III	N/A
<b>ANTIBODIES</b>				
<b>CHERUB 001</b> Intravenous immunoglobulin in primary HIV infection	No clinicaltrials.gov entry	CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC)	N/A	<a href="#">CROI 2017, Abstract 324</a>
<b>3BNC117</b>	<a href="#">NCT02018510</a>	Rockefeller University	Phase I	<a href="#">Nature. 2015 Jun 25;522(7557):487-91</a>
<b>VRC01</b>	<a href="#">NCT02411539</a>	NIAID	Phase I	N/A
<b>VRC01</b>	<a href="#">NCT02463227</a>	NIAID	Phase I	<a href="#">N Engl J Med. 2016 Nov 24;375(21):2037-2050</a> CROI 2016, Abstract 32LB, <a href="#">Webcast</a>

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>ANTIBODIES (Cont.)</b>				
VRC01	<a href="#">NCT01950325</a>	NIAID	Phase I	<a href="#">Sci Transl Med. 2015 Dec 23;7(319):319ra206</a>
<b>ANTI-FIBROTIC</b>				
ACE inhibitors	<a href="#">NCT01535235</a>	UCSF/amfAR	Phase IV	N/A
<b>ANTI-INFLAMMATORY</b>				
CC-11050 (phosphodiesterase-4 inhibitor)	<a href="#">NCT02652546</a>	NIAID	Phase I	N/A
<b>ANTIRETROVIRAL THERAPY</b>				
HIV reservoir dynamics after switching to dolutegravir in patients on a PI/r based regimen	<a href="#">NCT02513147</a>	Hospital Universitari Vall d'Hebron Research Institute	Phase IV	N/A
raltegravir or efavirenz + tenofovir + emtricitabine	<a href="#">NCT00734344</a>	University of Alabama at Birmingham	Phase IV	N/A
ABX464	<a href="#">NCT02735863</a>	Abivax S.A.	Phase II	N/A
<b>ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS</b>				
emtricitabine + rilpivirine + tenofovir	<a href="#">NCT01777997</a>	AIDS Clinical Trials Group/NIAID	Phase IV	N/A
raltegravir + tenofovir + emtricitabine	<a href="#">NCT01025427</a>	University of California, San Francisco	Phase IV	<a href="#">PLoS Pathog. 2013;9(10):e1003691</a>
<b>ASSEMBLY INHIBITOR</b>				
BIT225	<a href="#">ACTRN12612000696897</a>	Biotron Limited	Phase I	<a href="#">J Antimicrob Chemother. 2016 Mar;71(3):731-8</a>
<b>COMBINATIONS</b>				
chemotherapy + maraviroc in people with non-Hodgkin lymphoma	<a href="#">NCT02486510</a>	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase 0	Terminated due to futility criteria
ERAMUNE-01 (antiretroviral intensification +/- interleukin-7)	<a href="#">NCT01019551</a>	ORVACS/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer	Phase II	<a href="#">AIDS. 2016 Jan;30(2):221-30</a>
ERAMUNE-02 (DNA/Ad5 vaccine, ART intensification)	<a href="#">NCT00976404</a>	Vical/GenVec/CHERUB/NIH Vaccine Research Center/ORVACS	Phase II	CROI 2014, <a href="#">Poster abstract 422</a>

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>COMBINATIONS (Cont.)</b>				
<b>Vacc-4x + romidepsin</b>	<a href="#">NCT02092116</a>	Bionor Immuno AS/Celgene	Phase I/II	<a href="#">Lancet HIV 2016, July 7, 2016</a>
<b>Vacc-4x (peptide-based therapeutic vaccine) + lenalidomide</b>	<a href="#">NCT01704781</a>	Bionor Immuno AS	Phase I/II	IAS 2015 Towards an HIV Cure Symposium, <a href="#">Poster Abstract PE61</a>
<b>vorinostat + hydroxychloroquine + maraviroc (VHM)</b>	<a href="#">NCT02475915</a> <a href="#">NCT02470351</a> (CNS substudy)	South East Asia Research Collaboration with Hawaii	Phase I/II	AIDS 2016, <a href="#">Abstract TUAX0101LB</a>
<b>MVA-B (viral vector vaccine) +/- disulfiram</b>	<a href="#">NCT01571466</a>	Hospital Clinic of Barcelona/HIVACAT	Phase I	<a href="#">J Antimicrob Chemother. 2015 Feb 26. pii: dkv046.</a> <a href="#">PLoS One. 2015 Nov 6;10(11):e0141456.</a>
<b>GENE THERAPIES</b>				
<b>SB-728-T</b>	<a href="#">NCT01252641</a>	Sangamo BioSciences	Phase I/II	N/A
<b>SB-728-T</b>	<a href="#">NCT01044654</a>	Sangamo BioSciences	Phase I	ICAAC 2014, <a href="#">Abstract H-643</a> ; 2013, <a href="#">Abstract H-1464c</a>
<b>SB-728-T</b>	<a href="#">NCT00842634</a>	Sangamo Biosciences/University of Pennsylvania	Phase I	<a href="#">N Engl J Med. 2014 Mar 6;370(10):901–10</a>
Redirected high affinity Gag-specific T cells	<a href="#">NCT00991224</a>	University of Pennsylvania/Adaptimmune	Phase I	N/A
<b>HGTV43</b>	No clinicaltrials.gov entry	Enzo Biochem	Phase I	AIDS 2006, <a href="#">Abstract MOPDA06</a>
<b>GENE THERAPIES FOR HIV-POSITIVE PEOPLE WITH CANCERS</b>				
Stem cells gene-modified with M87o vector encoding HIV-inhibiting C46 peptide	<a href="#">NCT00858793</a>	Universitätsklinikum Hamburg-Eppendorf	Phase I/II	N/A

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>IMMUNE CHECKPOINT INHIBITORS</b>				
<b>BMS-936559</b> (anti-PD-L1 antibody)	<a href="#">NCT02028403</a>	National Institute of Allergy and Infectious Diseases (NIAID)	Phase I	CROI 2016, Abstract 25, <a href="#">Webcast</a>
<b>IRON CHELATORS</b>				
<b>deferiprone</b>	<a href="#">NCT02456558</a>	ApoPharma	Phase I	N/A
<b>LATENCY-REVERSING AGENTS</b>				
<b>disulfiram</b> (acetaldehyde dehydrogenase inhibitor)	<a href="#">NCT01286259</a>	University of California, San Francisco/ Johns Hopkins University/amfAR	Not specified	<a href="#">Clin Infect Dis. 2014 58 (6): 883–90</a>
<b>vorinostat</b> (HDAC inhibitor)	<a href="#">NCT01365065</a>	Bayside Health/Merck	Phase II	<a href="#">PLoS Pathog. 2014;10(10):e1004473</a>
<b>valproic acid</b> (HDAC inhibitor)	<a href="#">NCT00289952</a>	McGill University/Canadian Foundation for AIDS Research/CIHR Canadian HIV Trials Network	Phase II	<a href="#">HIV Med. 2012 May;13(5):291–6</a>
<b>valproic acid</b>	<a href="#">NCT00614458</a>	University of North Carolina at Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme Corp.	Phase II	<a href="#">PLoS One. 2010 5(2): e9390</a>
<b>MGN1703</b> toll-like receptor 9 (TLR-9) agonist	<a href="#">NCT02443935</a>	University of Aarhus	Phase Ib/IIa	<a href="#">Clin Infect Dis. 2017 Mar 9</a>
<b>Chidamide</b> (HDAC inhibitor)	<a href="#">NCT02513901</a>	Tang-Du Hospital	Phase I/II	N/A
<b>disulfiram</b>	<a href="#">NCT01944371</a>	University of California, San Francisco/Monash University/amfAR	Phase I/II	CROI 2015, <a href="#">Poster abstract 428LB</a>
<b>panobinostat</b> (HDAC inhibitor)	<a href="#">NCT01680094</a>	University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR	Phase I/II	<a href="#">The Lancet HIV. 2014 Oct; 1(1): e13–e21</a> CROI 2015, Abstract 109, <a href="#">Webcast</a>
<b>vorinostat</b>	<a href="#">NCT01319383</a>	University of North Carolina at Chapel Hill/NIAID/Merck	Phase I/II	<a href="#">Nature. 2012 Jul 25;487(7408):482-5</a> <a href="#">J Infect Dis. 2014 Sep 1;210(5):728-35</a>
<b>bryostatatin 1</b> (PKC agonist)	<a href="#">NCT02269605</a>	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	Phase I	<a href="#">AIDS. 2016 Feb 17. [Epub ahead of print]</a>

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>OBSERVATIONAL STUDIES</b>				
<b>ANRS EP 44:</b> Residual replication of HIV-1 in the gut associated lymphoid tissue (GALT)	<a href="#">NCT01038401</a>	French National Agency for Research on AIDS and Viral Hepatitis	N/A	N/A
<b>CHERUB 003</b> (prospective HIV chemotherapy cohort study)	<a href="#">NCT01902693</a>	Imperial College London/CHERUB	N/A	N/A
HIV resistance and treatment strategies	<a href="#">NCT00581802</a>	NIAID	N/A	N/A
In vitro autologous vaccine development to activate HIV reservoirs	UK CPMS17532 (link currently broken)	Imperial College London/amfAR	N/A	N/A
<b>MUCOVIR:</b> Exploration of HIV reservoirs	<a href="#">NCT01019044</a>	Objectif Recherche Vaccins SIDA	N/A	<a href="#">JAIDS. 2013 Mar 1;62(3):255-9</a>
Size of the HIV-1 reservoir and ongoing replication in defined cohorts	UK CPMS16004 (link currently broken)	University College London/amfAR	N/A	N/A
<b>Tat protein vaccine</b> (roll-over observational study for extended follow-up of volunteers in the ISS T-003 trial)	<a href="#">NCT02712489</a>	Barbara Ensoli, MD, Istituto Superiore di Sanità/Italian Ministry of Foreign Affairs	N/A	N/A
Tissue drug levels of HIV medications	<a href="#">NCT01490346</a>	University of Minnesota – Clinical and Translational Science Institute/NIAID	N/A	<a href="#">Proc Natl Acad Sci USA. 2014 Feb 11;111(6):2307-12.</a>
<b>ULTRASTOP</b> (Towards HIV Functional Cure) <b>ERAMUNE-03</b> (antiretroviral treatment interruption)	<a href="#">NCT01876862</a>	Objectif Recherche VACCin Sida (ORVACS)/Fondation Bettencourt Schueller	N/A	<a href="#">AIDS, Published Ahead-of-Print, January 4, 2016</a>
<b>VIRECT:</b> Impact of pre-ART CD4 T cell level on the rectal reservoir in long-term HIV-1 treated men	<a href="#">NCT02526940</a>	Centre Hospitalier Universitaire de Saint Etienne	N/A	N/A

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>STEM CELL TRANSPLANTATION</b>				
Immune response after stem cell transplant in HIV-positive patients with hematologic cancer	<a href="#">NCT00968630</a>	Fred Hutchinson Cancer Research Center	Phase II	N/A
<b>THERAPEUTIC VACCINES</b>				
<b>AGS-004</b> (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens)	<a href="#">NCT00672191</a>	Argos Therapeutics	Phase IIb	<a href="#">J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8</a>
<b>AGS-004</b>	<a href="#">NCT01069809</a>	Argos Therapeutics	Phase IIb	IAS 2015 Towards an HIV Cure Symposium, <a href="#">Combination Therapy Trials Roundtable</a> CROI 2014, <a href="#">Poster abstract 344</a>
<b>DermaVir</b> (topically applied DNA vaccine)	<a href="#">NCT00711230</a>	Genetic Immunity	Phase II	N/A
<b>DermaVir</b>	<a href="#">NCT00918840</a>	Genetic Immunity	Phase II	N/A
<b>GSK Biologicals HIV Vaccine 732462</b> (p24-RT-Nef-p17 fusion protein vaccine)	<a href="#">NCT01218113</a>	GlaxoSmithKline	Phase II	<a href="#">Medicine (Baltimore). 2016 Feb;95(6):e2673</a>
<b>Tat protein vaccine</b>	<a href="#">NCT01513135</a>	Barbara Ensoli, MD, Istituto Superiore di Sanità/Italian Ministry of Foreign Affairs	Phase II	N/A
<b>Tat protein vaccine</b>	<a href="#">NCT01513135</a>	Barbara Ensoli, MD, Istituto Superiore di Sanità	Phase II	<a href="#">Retrovirology. 2015 Apr 29;12(1):33</a> <a href="#">PLoS One. 2010 Nov 11;5(11):e13540</a>
<b>Vacc-4x</b> (peptide-based vaccine)	<a href="#">NCT00659789</a>	Bionor Immuno AS	Phase II	<a href="#">Lancet Infect Dis. 2014 Apr;14(4):291-300</a>
<b>VAC-3S</b> (peptide-based vaccine)	<a href="#">NCT01549119</a>	InnaVirVax	Phase I/IIa	30 Years of HIV Science, 2013, <a href="#">poster abstract 145</a> IAS 2015 Towards an HIV Cure Symposium, <a href="#">Poster Abstract PE67 LB</a>

**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>THERAPEUTIC VACCINES (Cont.)</b>				
<b>AGS-004</b>	<a href="#">NCT02042248</a>	University of North Carolina at Chapel Hill/Argos Therapeutics/U.S. National Institutes of Health (NIH)	Phase I/II	N/A
<b>Autologous HIV-1 ApB DC Vaccine</b>	<a href="#">NCT00510497</a>	Sharon Riddler, University of Pittsburgh/NIAID	Phase I/II	<a href="#">J Infect Dis. 2016 May 1;213(9):1400-9</a>
<b>Dendritic cells pulsed with chemically inactivated HIV</b>	<a href="#">NCT02766049</a>	University of Sao Paulo General Hospital	Phase I/II	<a href="#">J Int AIDS Soc. 2014 Jan 10;17:18938</a> <a href="#">J. Cellular Immunotherapy xx (2016) 1-10</a>
<b>Dendritic cell vaccine</b>	<a href="#">NCT00833781</a>	Massachusetts General Hospital	Phase I/II	N/A
<b>Dendritic cell vaccine (DCV-2)</b>	<a href="#">NCT00402142</a>	Hospital Clinic of Barcelona	Phase I/II	<a href="#">Sci Transl Med. 2013 Jan 2;5(166):166ra2</a>
<b>DermaVir</b>	<a href="#">NCT00270205</a>	AIDS Clinical Trials Group	Phase I/II	<a href="#">JAIDS. 2013 Dec 1;64(4):351-9</a>
<b>GTU®-MultiHIV B Clade Vaccine</b>	<a href="#">NCT02457689</a>	Imperial College London	Phase I/II	N/A
<b>TUTI-16 (synthetic HIV-1 Tat epitope vaccine)</b>	<a href="#">NCT01335191</a>	Thymon, LLC	Phase I/II	<a href="#">Hum Vaccin Immunother. 2012 Oct;8(10):1425-30</a>
<b>Vacc-C5 (peptide-based vaccine)</b>	<a href="#">NCT01627678</a>	Bionor Immuno AS	Phase I/II	N/A
<b>AFO-18 (peptide-based vaccine)</b>	<a href="#">NCT01141205</a>	Statens Serum Institut (SSI)/Ministry of the Interior and Health, Denmark/European and Developing Countries Clinical Trials Partnership (EDCTP)	Phase I	<a href="#">AIDS Res Hum Retroviruses. 2013 Nov;29(11):1504-12</a>
<b>AFO-18 (peptide-based vaccine)</b>	<a href="#">NCT01009762</a>	SSI/Rigshospitalet/Hvidovre University Hosp./Ministry of Interior & Health, Denmark	Phase I	<a href="#">Clin Immunol. 2013 Feb;146(2):120-30</a>
<b>AT20-KLH</b>	MED-AT20-001	Medestea Research & Production SpA, Turin	Phase I	<a href="#">Vaccine. 2014 Feb 19;32(9):1072-8</a>
<b>ChAdV63.HIVcons + MVA.HIVconsv (viral vector vaccines)</b>	<a href="#">NCT01712425</a>	IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford	Phase I	IAS 2015, <a href="#">Poster abstract MOPEA036</a>



**Table 3. Completed Studies (Cont.)**

Trial	Trial Registry Identifier(s)	Manufacturer/ Sponsor(s)	Phase	Published/Presented Data
<b>THERAPEUTIC VACCINES (Cont.)</b>				
<b>Dendritic cells loaded with HIV-1 lipopeptides</b>	<a href="#">NCT00796770</a>	Baylor Research Institute/ANRS	Phase I	<a href="#">Retrovirology 2012, 9(Suppl 2):P328</a>
<b>DermaVir</b>	<a href="#">NCT00712530</a>	Genetic Immunity	Phase I	<a href="#">PLoS One. 2012 7(5): e35416</a>
<b>D-GPE DNA + M-GPE MVA</b> (DNA + viral vector vaccines)	<a href="#">NCT01881581</a>	Centers for Disease Control and Prevention, China	Phase I	N/A
<b>HIVAX</b> (lentiviral vector-based therapeutic vaccine)	<a href="#">NCT01428596</a>	GeneCure Biotechnologies	Phase I	<a href="#">Vaccine. 2016 Apr 27;34(19):2225-32</a>
<b>HIV-v</b> (peptide-based vaccine)	<a href="#">NCT01071031</a>	PepTcell Limited	Phase I	<a href="#">Vaccine. 2013 Nov 19;31(48):5680-6</a>
<b>JS7 DNA + MVA62B</b> (DNA + viral vector vaccines)	<a href="#">NCT01378156</a>	GeoVax, Inc.	Phase I	<a href="#">HIV R4P 2014, Abstract OA05.03 (webcast)</a>
<b>MAG pDNA vaccine +/- IL-12</b>	<a href="#">NCT01266616</a>	NIAID	Phase I	N/A
<b>MVA.HIVconsv</b>	<a href="#">NCT01024842</a>	University of Oxford/Medical Research Council	Phase I	N/A
<b>PENNVAX-B (Gag, Pol, Env) + electroporation</b>	<a href="#">NCT01082692</a>	Inovio Pharmaceuticals	Phase I	<a href="#">Retrovirology 2012, 9(Suppl 2):P276</a>
<b>PENNVAX-B +/- IL-12 or IL-15</b>	<a href="#">NCT00775424</a>	University of Pennsylvania	Phase I	N/A
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT</b>				
Anti-HIV medications for people recently infected with HIV	<a href="#">NCT00106171</a>	NIAID	Phase IV	<a href="#">PLoS One. 2015 10(11):e0143259</a>
<b>enfuvirtide</b>	<a href="#">NCT00051831</a>	NIAID	Not listed	<a href="#">J Infect Dis. 2010 Jan 15;201(2):293-6</a>
<b>enfuvirtide</b>	<a href="#">NCT00334022</a>	Canadian Immunodeficiency Research Collaborative	Not listed	N/A
<b>PLUS:</b> Pilot study on the effect of adding raltegravir +/- a second drug on HIV levels in the gut	<a href="#">NCT00884793</a>	University of California, San Francisco	Not listed	<a href="#">J Infect Dis. 2010 Nov 15;202(10):1553-61</a> <a href="#">AIDS. 2010 Oct 23;24(16):2451-60</a>

Table 3. Completed Studies (Cont.)

Trial	Trial Registry Identifier(s)	Manufacturer/Sponsor(s)	Phase	Published/Presented Data
<b>TREATMENT INTENSIFICATION/EARLY TREATMENT (Cont.)</b>				
<b>ANRS 147 OPTIPRIM:</b> Optimization of primary HIV-1 infection treatment	<a href="#">NCT01033760</a>	French National Institute for Health and Medical Research–French National Agency for Research on AIDS and Viral Hepatitis (Inserm–ANRS)	Phase III	<a href="#">PLoS One. 2013; 8(5): e64219.</a> <a href="#">PLoS One. 2013; 8(3): e59767</a> IAS 2013, <a href="#">Abstract WEAB0101</a> IAS Cure Symposium, <a href="#">Presentation</a>
<b>maraviroc</b>	<a href="#">NCT00808002</a>	Germans Trias i Pujol Hospital	Phase III	<a href="#">AIDS. 2014 Jan 28;28(3):325–34</a>
<b>raltegravir + maraviroc</b>	<a href="#">NCT00935480</a>	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	Phase III	N/A
<b>raltegravir</b>	<a href="#">NCT00554398</a>	Germans Trias i Pujol Hospital	Phase III	<a href="#">Antivir Ther. 2012;17(2):355–64</a>
Intense acute infection study	<a href="#">NCT01154673</a>	University of Toronto	Phase II/III	N/A
<b>maraviroc</b>	<a href="#">NCT00795444</a>	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal/Pfizer	Phase II	<a href="#">PLoS One. 2011; 6(12):e27864</a> <a href="#">AIDS. 2013 Aug 24; 27(13):2081-8.</a>
<b>raltegravir</b>	<a href="#">NCT00520897</a>	Canadian Immunodeficiency Research Collaborative	Phase II	<a href="#">AIDS. 2012 Jan 14;26(2):167–74</a>
<b>raltegravir</b>	<a href="#">NCT00807443</a>	Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal	Phase II	<a href="#">AIDS. 2012 Sep 24;26(15):1885–94</a>
Viral suppression after analytic treatment interruption in Thai patients who initiated HAART during acute HIV infection	<a href="#">NCT02614950</a>	South East Asia Research Collaboration with Hawaii	Phase II	CROI 2017, Abstract 124, <a href="#">Webcast</a>
<b>alpha interferon intensification</b>	<a href="#">NCT01295515</a>	NIAID	Phase I/II	N/A
<b>indinavir + zidovudine + lamivudine + nevirapine</b>	<a href="#">NCT00001644</a>	NIAID	Phase I	N/A